Foresee Pharmaceuticals Co., Ltd.

10:45 AM - 11:00 AM (EDT), Wednesday, October 23, 2019 ・ 2nd Floor
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange. Foresee’s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology and derived drug products targeting specialty markets, and its transformative preclinical and clinical first-in-class NCE programs targeting disease areas with high unmet needs. Foresee's product portfolio includes late stage and early stage programs such as FP-001, 6-month and 3-month, stable, ready-to-use versions of leuprolide mesylate depot for injection, for which regulatory submissions are planned in 2020, FP-025, a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in a Phase 2 proof-of-concept study; FP-045, a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently in planning (Fanconi Anemia; mitochondrial-mediated diseases).
Ticker:
6576
Exchange:
TPEx
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Taiwan
Year Founded:
2013
Main Therapeutic Focus:
Lead Product in Development:
FP-001
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
4